HIV PEP/PrEP

Quick links

The USPSTF found convincing evidence that PrEP (pre-exposure prophylaxis) is of substantial benefit for decreasing the risk of HIV infection in persons at high risk of HIV infection, either via sexual acquisition or through injection drug use. The USPSTF also found convincing evidence that adherence to PrEP is highly correlated with its efficacy in preventing the acquisition of HIV infection.

An estimated 1.1 million individuals in the United States are currently living with HIV.  In 2017, there were 38,281 new diagnoses of HIV infection reported in the United States; 81% (30,870) of these new diagnoses were among males and 19% (7312) were among females. Although treatable, HIV infection has no cure and has significant health consequences.

Prescribing HIV PrEP and PEP (post-exposure prophylaxis) to the right populations will significantly decrease incident cases and is well within the scope of practice for primary care.  Here you will find the full guidelines for prescribing and monitoring these medications along with a quick cheat sheet to get a birds eye view of who should be screened, treated and monitored.  There are a number of local organizations that offer free outreach for HIV testing as well as for other STIs (Terros, Native Health, Southwest Center for HIV/AIDS).

The medications are extremely expensive and are available through the pharmaceutical companies Patient Assistance Program (see medications) or through their copay discount program where the copay is typically waived.

 If there are any questions about starting PEP, PrEP or treatment for HIV the Clinician consult center is a great resource, the web address is https://nccc.ucsf.edu/

The PrEP number is 855-448-7737 (855-HIV-PrEP) and the PEP number is 855-448-4911.